Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
66.20    -1.80 (-2.65%)
Bid:
65.90
Ask:
66.70
Spread: 0.80 (1.214%)
Market Cap: £584.83m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Year-end update

30 Jan 2024 17:15

RNS Number : 4255B
IP Group PLC
30 January 2024
 

FOR RELEASE ON

30 January 2024

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU NO. 596/2014) WHICH FORMS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.

 

IP Group plc - year-end update

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, issues an unaudited year-end update ahead of its results for the 12 months to 31 December 2023 now that the Group's usual year-end process is sufficiently progressed.

The market environment for early-stage investing remained challenging in 2023 and, against this backdrop, we saw some further softening of valuations in the final quarter of 2023. As a result, the Directors currently expect NAV per share to be between 111 pence and 117 pence at the year end.

Within this context, many of the Group's leading portfolio companies made strong progress, with some significant inflection points expected in 2024.

The Group continues to appropriately manage its investment levels and remains in a strong financial position with gross cash and deposits of £227m at year-end.

IP Group expects to announce its 2023 results on Wednesday 13 March 2024 following the completion of our usual year end valuations process.

 

Notes

The share price of Oxford Nanopore Technologies plc was approximately 208 pence at the end of 2023.- This update is based on unaudited information and is subject to change following the completion of the Group's usual full year-end reporting process and annual audit.- This announcement may contain forward looking statements. These statements reflect the Board's current view, are subject to several material risks and uncertainties and could change in the future. Factors which could cause or contribute to such changes include, but are not limited to, the general economic climate and market conditions, as well as specific factors relating to the financial or commercial prospects or performance of individual companies within the Group's portfolio.

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7967 312125

Portland

Vic Wallin

Alex Donaldson

+44 (0) 7973 823119

+44 (0) 7516 729702

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science investor, we develop and support some of the world's most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO. For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTGZGFMNGNGDZM
Date   Source Headline
14th Nov 20257:00 amRNSTransaction in Own Shares
13th Nov 20254:09 pmRNSHolding(s) in Company
13th Nov 20257:00 amRNSTransaction in Own Shares
12th Nov 20257:00 amRNSTransaction in Own Shares
11th Nov 20254:45 pmRNSHolding(s) in Company
10th Nov 20256:02 pmRNSTransaction in Own Shares
10th Nov 20257:00 amRNSTransaction in Own Shares
7th Nov 20254:51 pmRNSHolding(s) in Company
7th Nov 20257:00 amRNSTransaction in Own Shares
6th Nov 20257:00 amRNSTransaction in Own Shares
5th Nov 20255:14 pmRNSHolding(s) in Company
4th Nov 20256:23 pmRNSTransaction in Own Shares
4th Nov 20257:00 amRNSTransaction in Own Shares
31st Oct 20255:25 pmRNSTotal Voting Rights
31st Oct 20255:19 pmRNSTransaction in Own Shares
31st Oct 20257:00 amRNSTransaction in Own Shares
29th Oct 20255:27 pmRNSTransaction in Own Shares
28th Oct 20256:06 pmRNSTransaction in Own Shares
28th Oct 20257:00 amRNSTransaction in Own Shares
24th Oct 20255:31 pmRNSTransaction in Own Shares
24th Oct 20257:00 amRNSTransaction in Own Shares
22nd Oct 20255:30 pmRNSTransaction in Own Shares
22nd Oct 20257:00 amRNSTransaction in Own Shares
21st Oct 20257:00 amRNSTransaction in Own Shares
17th Oct 20255:59 pmRNSTransaction in Own Shares
16th Oct 20255:45 pmRNSTransaction in Own Shares
15th Oct 20255:20 pmRNSTransaction in Own Shares
15th Oct 20257:00 amRNSTransaction in Own Shares
14th Oct 20256:18 pmRNSHolding(s) in Company
13th Oct 20257:00 amRNSPotential income from Metsera obesity drugs
10th Oct 20255:17 pmRNSTransaction in Own Shares
10th Oct 20257:00 amRNSTransaction in Own Shares
9th Oct 20257:00 amRNSTransaction in Own Shares
8th Oct 20257:00 amRNS-RPortfolio co Monolith to be acquired by CoreWeave
7th Oct 20255:21 pmRNSTransaction in Own Shares
6th Oct 20255:56 pmRNSTransaction in Own Shares
6th Oct 20257:00 amRNSTransaction in Own Shares
3rd Oct 20257:00 amRNSTransaction in Own Shares
1st Oct 20255:23 pmRNSTransaction in Own Shares
30th Sep 20256:05 pmRNSTotal Voting Rights
30th Sep 20256:03 pmRNSTransaction in Own Shares
30th Sep 20257:00 amRNSTransaction in Own Shares
29th Sep 20257:00 amRNS-RPortfolio co OXCCU completes £20.75m funding round
26th Sep 20255:36 pmRNSTransaction in Own Shares
26th Sep 20257:00 amRNSTransaction in Own Shares
24th Sep 20255:36 pmRNSTransaction in Own Shares
24th Sep 20257:00 amRNSTransaction in Own Shares
23rd Sep 20257:00 amRNSTransaction in Own Shares
19th Sep 20254:55 pmRNSTransaction in Own Shares
18th Sep 20255:24 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.